Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Bladder Cancer

Free Subscription 20.10.2025 1 Adv Sci (Weinh) 2 Am J Surg Pathol 2 BJU Int 1 BMC Cancer 1 BMC Urol 1 Can Urol Assoc J 1 Cancer Chemother Pharmacol 1 Cancer Cytopathol 1 Cancer Res Treat 3 Cancers (Basel) 2 Clin Cancer Res 1 Contemp Oncol (Pozn) 2 Cureus 1 Diagn Pathol 3 Discov Oncol 3 Eur Urol 1 Eur Urol Focus 1 Eur Urol Oncol 1 FASEB J 1 Front Biosci (Landmark Ed) 1 Front Immunol 3 Front Oncol 2 Histopathology 1 Int J Mol Sci 1 Int J Urol 1 J Clin Med 1 J Dermatol 1 J Med Case Rep 1 J Med Econ 1 J Nucl Med 1 J Robot Surg 1 Medicine (Baltimore) 1 Nucl Med Commun 1 Oncol Rep 1 PLoS One 2 Sci Rep 1 Talanta 1 Urol Case Rep 1 Urol Int 1 Urol Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Sci (Weinh)

1. SHEN R, Jiang F, Huang X, Hong G, et al
   Artificial Intelligence-Assisted Urine Cytology for Noninvasive Detection of Muscle-Invasive Urothelial Carcinoma: A Multi-Center Diagnostic Study with Prospective Validation.
   Adv Sci (Weinh). 2025;12:e08977.
   PubMed         Abstract available
   
   

   
   Am J Surg Pathol

2. REIS H, Al-Ahmadie H, Gaisa NT, Lopez-Beltran A, et al
   The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms.
   Am J Surg Pathol. 2025;49:e18-e26.
   PubMed         Abstract available
   
   
3. CHEN J, Daniels E, Mirsadraei L, Skala SL, et al
   Clinicopathologic Review of Malignancies in Neobladders and Conduits Following Bladder Reconstruction.
   Am J Surg Pathol. 2025;49:1150-1157.
   PubMed         Abstract available
   
   

   
   BJU Int

4. BRANDT SB, Korner SK, Milling RV, Nielsen NK, et al
   Ureteroenteric strictures following retrosigmoid vs. conventional ileal conduit - The MOSAIC study (The DaBlaCa-16 study).
   BJU Int. 2025;136:858-865.
   PubMed         Abstract available
   
   
5. MASTROIANNI R, Chiacchio G, Tuderti G, Brassetti A, et al
   Stapled vs totally handsewn robotic intracorporeal neobladder: perioperative and functional outcomes.
   BJU Int. 2025;136:866-871.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. LI W, Shi Y, Pu L, Zhang J, et al
   Shared decision-making in urinary reconstruction among radical cystectomy patients: a thematic analysis of patient and provider perspectives in China.
   BMC Cancer. 2025;25:1590.
   PubMed         Abstract available
   
   

   
   BMC Urol

7. QI W, Qisheng L, Weiyang W, Yuan L, et al
   Integrating urinary dual-gene methylation and VI-RADS score to predict residual tumors after TURBT in NMIBC: a nomogram-based model.
   BMC Urol. 2025;25:255.
   PubMed         Abstract available
   
   

   
   Can Urol Assoc J

8. POWER N
   Guideline adherence in treating non-muscle-invasive bladder cancer: Discipline can save lives.
   Can Urol Assoc J. 2025;19:311.
   PubMed        
   
   

   
   Cancer Chemother Pharmacol

9. PRASAD SM, Louie MJ, Burger B, Tsurutis V, et al
   Pharmacokinetics of UGN?102, an investigational mitomycin?containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer.
   Cancer Chemother Pharmacol. 2025;95:100.
   PubMed         Abstract available
   
   

   
   Cancer Cytopathol

10. FURUHATA A, Teramoto Y, Minamiguchi S, Hirata M, et al
    Neutrophil-calibrated atypical squamous cells in ThinPrep urine cytology for detecting squamous differentiation in urothelial carcinoma.
    Cancer Cytopathol. 2025;133:e70055.
    PubMed         Abstract available
    
    

    
    Cancer Res Treat

11. PARK I, Yoon S, Kim I, Park K, et al
    Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05).
    Cancer Res Treat. 2025;57:1167-1177.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

12. DEL GIUDICE F, Santarelli V, Spurna K, Ali Kirmani SG, et al
    Contemporary Trends and Predictors of pT0 in Radical Cystectomy Specimens Among Non-Muscle and Muscle-Invasive Bladder Cancer Patients: A Propensity Score-Matched Analysis from a Single Tertiary Centre in the United Kingdom.
    Cancers (Basel). 2025;17:3110.
    PubMed         Abstract available
    
    
13. ALBERS ACOSTA E, Pelari Mici L, Guemez CM, Velasco Balanza C, et al
    Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer.
    Cancers (Basel). 2025;17:3261.
    PubMed         Abstract available
    
    
14. JAIME-CASAS S, Yip W, Lama DJ, Goes V, et al
    Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2025;17:3265.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

15. HEISS BL, Chang E, Joeng HK, Fiero MH, et al
    FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.
    Clin Cancer Res. 2025;31:4223-4229.
    PubMed         Abstract available
    
    
16. LIU Z, Zhang L, Jin K, Zeng H, et al
    ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.
    Clin Cancer Res. 2025;31:4311-4322.
    PubMed         Abstract available
    
    

    
    Contemp Oncol (Pozn)

17. WANG R, Xu Z, Ding Z, Ge J, et al
    Integrated Mendelian randomization analysis reveals causal relationship between LAMA5 and bladder cancer and its metabolic mechanisms.
    Contemp Oncol (Pozn). 2025;29:287-296.
    PubMed         Abstract available
    
    

    
    Cureus

18. ROCHA JM, Fernandes R, Queiros L, Rodrigues J, et al
    Therapy-Related Toxicity in Bladder Cancer Treatment: A Case Report.
    Cureus. 2025;17:e91905.
    PubMed         Abstract available
    
    
19. HADZIOSMANOVIC O, Kulovac B, Valjevac A, Fajkic A, et al
    Influence of Glutathione S-transferase Mu 1 (GSTM1), Glutathione S-transferase Theta 1 (GSTT1), and N-acetyltransferase 2 (NAT2) Variants on Bladder Cancer Progression and Recurrence Rating: A Bosnian and Herzegovinian Case-Control Study.
    Cureus. 2025;17:e91948.
    PubMed         Abstract available
    
    

    
    Diagn Pathol

20. HALAVA V, Tuominen J, Lindholm P, Kyyronen T, et al
    EWSR1::BEND2 fusion sarcoma of the urinary bladder - a case report and review of literature.
    Diagn Pathol. 2025;20:116.
    PubMed         Abstract available
    
    

    
    Discov Oncol

21. MANSOUR R, Tarhini F, Bruce N, Blanche J, et al
    In vitro assessment of benzothiadiazole-based photoactive polymers against ovarian, prostate and bladder cancer cell lines for photodynamic therapy.
    Discov Oncol. 2025;16:1863.
    PubMed         Abstract available
    
    
22. CHANG Z, Wang J, Wang L, Hu Z, et al
    Circulating metabolites and bladder cancer: a Mendelian randomization and multi-omics study.
    Discov Oncol. 2025;16:1859.
    PubMed         Abstract available
    
    
23. CHEN Y, Yu Q, Jiang X, Li L, et al
    Identifying the causal role and therapeutic potential of immune-related genes in bladder cancer: a Mendelian randomization study.
    Discov Oncol. 2025;16:1857.
    PubMed         Abstract available
    
    

    
    Eur Urol

24. BUISAN O, Servian P, Pedreno-Lopez S, Pages J, et al
    A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guerin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.
    Eur Urol. 2025 Oct 14:S0302-2838(25)00505-6. doi: 10.1016/j.eururo.2025.
    PubMed         Abstract available
    
    
25. CHU CE, Chen Z, Whiting K, Ostrovnaya I, et al
    Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.
    Eur Urol. 2025;88:472-481.
    PubMed         Abstract available
    
    
26. DE WIT R, Vaughn DJ, Fradet Y, Fong L, et al
    Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
    Eur Urol. 2025;88:462-471.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

27. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
    Survival Rates in Trimodal Therapy Versus Radiotherapy in Urothelial Carcinoma of Urinary Bladder.
    Eur Urol Focus. 2025;11:251-257.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

28. LI R, Hensley PJ, Babjuk M, Bukavina L, et al
    Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group.
    Eur Urol Oncol. 2025 Oct 10:S2588-9311(25)00223.
    PubMed         Abstract available
    
    

    
    FASEB J

29. YANG T, Guo L, Kong S, Xu Q, et al
    The lncRNA MIR4435-2HG Modulates Bladder Cancer Progression and Ferroptosis Through the IQGAP3/Ras/ERK/CREB Pathway.
    FASEB J. 2025;39:e71119.
    PubMed         Abstract available
    
    

    
    Front Biosci (Landmark Ed)

30. LEI J, Wang P, Qu Y, Wang X, et al
    Identification of TRIM59 as a Key Biomarker for Ferroptosis Resistance and Immunotherapy Response in Bladder Cancer via Multi-Omics Integration and Machine Learning.
    Front Biosci (Landmark Ed). 2025;30:44395.
    PubMed         Abstract available
    
    

    
    Front Immunol

31. LI F, Wang D, Gao Y, Cui Y, et al
    Bladder cancer immunotherapy parallel advances in BCG optimization and next-generation vaccine platforms.
    Front Immunol. 2025;16:1648698.
    PubMed         Abstract available
    
    

    
    Front Oncol

32. LISSON CG, Gallee L, Muller K, Manoj S, et al
    Machine learning-based radiomics for bladder cancer staging: evaluating the role of imaging timing in differentiating T2 from T3 disease.
    Front Oncol. 2025;15:1591742.
    PubMed         Abstract available
    
    
33. YU ZJ, Xu XD, Zou XC, Su P, et al
    Ensemble machine learning models for predicting bone metastasis in bladder cancer.
    Front Oncol. 2025;15:1653506.
    PubMed         Abstract available
    
    
34. DAMAJ N, Naim N, Saad A, Kattan C, et al
    Management of bladder cancer recurrence following the trimodality therapy.
    Front Oncol. 2025;15:1672431.
    PubMed         Abstract available
    
    

    
    Histopathology

35. ZHAO T, Akgul M, Siegmund SE
    Clinicopathologic, immunohistochemical and genomic characterization of urothelial carcinoma with myxoid and chordoid features.
    Histopathology. 2025;87:757-767.
    PubMed         Abstract available
    
    
36. DOWNES MR, Lajkosz K, Algaba F, Allory Y, et al
    Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology study.
    Histopathology. 2025;87:649-659.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

37. LEVY J, Sakatani T, Murakami K, Kita Y, et al
    Comparative Analysis of CT and MRI Combined with RNA Sequencing for Radiogenomic Staging of Bladder Cancer.
    Int J Mol Sci. 2025;26:9570.
    PubMed         Abstract available
    
    

    
    Int J Urol

38. KUKIMOTO T, Nakamura Y, Hata S, Shimada H, et al
    Expression of Glucocorticoid Receptor Beta in Bladder Cancer and Its Clinicopathological Significance: A Novel Diagnostic Marker to Predict Progression and Recurrence of Cancer.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70254.
    PubMed         Abstract available
    
    

    
    J Clin Med

39. SPIRITO L, Tammaro S, Coppola P, Manfredi C, et al
    Association Between Baseline Neutrophil-to-Lymphocyte Ratio and Short-Term Urinary Quality of Life During BCG Induction in Male Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study.
    J Clin Med. 2025;14:6908.
    PubMed         Abstract available
    
    

    
    J Dermatol

40. KUMA Y, Kido-Nakahara M, Kuba-Fuyuno Y, Matsumoto T, et al
    Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.
    J Dermatol. 2025;52:1584-1588.
    PubMed         Abstract available
    
    

    
    J Med Case Rep

41. SCHOLTE R, Hinrichs C
    Bladder carcinoma in a bladder diverticulum: a case report.
    J Med Case Rep. 2025;19:508.
    PubMed         Abstract available
    
    

    
    J Med Econ

42. MENG Y, Zhang S, Aout M, Babcock A, et al
    Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.
    J Med Econ. 2025;28:1779-1797.
    PubMed         Abstract available
    
    

    
    J Nucl Med

43. EDER AC, Omrane MA, El Fakiri M, Wielenberg CF, et al
    First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [(68)Ga]Ga-BCY25286.
    J Nucl Med. 2025 Oct 16:jnumed.125.269882. doi: 10.2967/jnumed.125.269882.
    PubMed        
    
    

    
    J Robot Surg

44. ANCESCHI U, Basile S, Amparore D, Di Maida F, et al
    "Far beyond the shape": an early head-to-head comparative urodynamic analysis of three contemporary totally intracorporeal robotic orthotopic neobladder techniques.
    J Robot Surg. 2025;19:689.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

45. HUANG M
    Global burden and inequalities of bladder cancer attributable to high fasting plasma glucose: Trends 1990-2021 and Projections to 2040.
    Medicine (Baltimore). 2025;104:e45255.
    PubMed         Abstract available
    
    

    
    Nucl Med Commun

46. IBRAHIM D, Abdelghaffar A, Nabil Hassan EE
    Added value of delayed imaging after diuretic injection in evaluation of cases of bladder cancer with PET.
    Nucl Med Commun. 2025 Oct 15. doi: 10.1097/MNM.0000000000002056.
    PubMed         Abstract available
    
    

    
    Oncol Rep

47. ZHU D, Wan X, Huang H, Chen X, et al
    [Expression of Concern] Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell?like side population cells.
    Oncol Rep. 2026;55:1.
    PubMed         Abstract available
    
    

    
    PLoS One

48. PARK Y, Xu W, Yang T, Hill V, et al
    STAG2 regulates polycomb and differentiation in urothelial precursors and bladder cancer.
    PLoS One. 2025;20:e0333128.
    PubMed         Abstract available
    
    

    
    Sci Rep

49. ZHU X, Yin X, Niu L, Yang G, et al
    Cerium oxide-embedded gold nanoparticles loaded with astragaloside IV for bladder cancer therapy.
    Sci Rep. 2025;15:36067.
    PubMed         Abstract available
    
    
50. ZUO M, Liao Y, He P, Zhu Y, et al
    p53 and PD-1/PD-L1 expression contribute to disease progression and are correlated to immune infiltrates in urothelial carcinoma.
    Sci Rep. 2025;15:36072.
    PubMed         Abstract available
    
    

    
    Talanta

51. LONG Z, Feng S, Xu Y, Yu J, et al
    Multi-parameter precise molecular profiling of bladder cancer based on aptamer probe package.
    Talanta. 2025;298.
    PubMed         Abstract available
    
    

    
    Urol Case Rep

52. BEDORE SR, Shin DH, van der Eerden J, Town MV, et al
    Pembrolizumab-induced myasthenia gravis: A rare immune-related adverse event in a patient treated for bladder cancer.
    Urol Case Rep. 2025;63:103226.
    PubMed         Abstract available
    
    

    
    Urol Int

53. GALLARDO ZAMORA L, Hohage J, Degener S, Dotse J, et al
    Cancer Reporting Protocols in transurethral resection of bladder tumor (TURBT) - standardized reporting of bladder cancer and improvement of communication between pathologists and urologists.
    Urol Int. 2025 Oct 16:1-13. doi: 10.1159/000548723.
    PubMed         Abstract available
    
    

    
    Urol Oncol

54. HONG JL, Chen C, Liu X, Cristescu R, et al
    Prevalence of therapeutic or disease-relevant oncogenic alterations: An analysis of the AACR Project GENIE Biopharma Cooperative bladder cancer cohort.
    Urol Oncol. 2025 Oct 15:S1078-1439(25)00353.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.